Mylan Recalls Batch of Insulin Pens Due to Missing Label Risk

Mylan Pharmaceuticals is recalling a batch of its Insulin Glargine (insulin glargine-yfgn) injection, 3 milliliter prefilled pens because of the potential for missing labels.

The company noted the risk of a missing label leading to a mix-up of products and strengths, which may result in either high or low blood sugar and lead to complications.

The recall affects the company’s unbranded interchangeable biosimilar insulin glargine pens, but not the branded Semglee injection pens.

The affected batch was distributed between April 4 and May 5 of this year.